Now published in the European Society for Medical Oncology’s (ESMO) flagship journal, Annals of Oncology, ESMO’s Clinical Practice Guideline for…
The countdown is now on as we get ready to attend the European Society for Medical Oncology’s (ESMO) premier and…
The phase III international CheckMate 9ER trial continues to make headlines. Now published ahead of print in The Lancet Oncology…
The 12th Annual two-day WIN Symposium 2022, co-chaired by Richard L. Schilsky and our Director, Josep Tabernero, Chairman and Vice-Chairman…
The “J-BID – José Baselga Innovative Disruption Program” has an investment of up to 6 million euros and aims to…
Barcelona, June 10th, 2022. In an invited Comment article recently published online first in The Lancet Oncology (1) , co-authors Elena…
For the first time in the context of brain metastasis, VHIO-led research has evidenced the striking preclinical efficacy of a…
Presented by VHIO’s Ana Oaknin during this week’s American Society of Clinical Oncology’s (ASCO) Annual Meeting, 03 – 07 June…
On the ground in Chicago at this week’s American Society of Clinical Oncology (ASCO) Annual Meeting, 03 – 07 June…
Developed in-house by VHIO’s Cancer Genomics Group, the VIGex gene-expression signature was initially validated at the Research Unit for Molecular…
Primary results from the multicenter TROPiCS-02 phase III point to the clinical benefit of novel antibody-drug conjugate sacituzumab govitecan in…
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and overall…
